Of course the ChatGPT dog cancer vaccine spawned a startup
Australian entrepreneur Paul Conyngham has launched Gamgee, a startup offering personalised mRNA cancer vaccines for dogs after claiming AI-assisted work helped shrink his dog Rosie’s tumours. The venture matters because it turns a widely publicised but disputed story about AI and canine cancer treatment into a commercial clinical offering, with longer-term ambitions to develop treatments for humans.
Gamgee is backed by Y Combinator and is recruiting for initial clinical trials in Australia, while maintaining an international waitlist. It cites a roughly 75 per cent tumour reduction in its first documented case and says a vaccine could be ready in about four weeks, but acknowledges this is based on one case; researchers have said Rosie’s improvement cannot be attributed clearly to the vaccine because she received another treatment at the same time.
- AI-linked dog cancer claim becomes a startup
- Evidence rests largely on one unclear case
- Gamgee plans Australian trials and broader ambitions
New here? Start with this
mRNA vaccines use genetic instructions to prompt the immune system to recognise a particular target. In cancer treatment, researchers are exploring personalised versions designed around mutations found in an individual patient’s tumour, rather than using one vaccine for every animal or person.
Paul Conyngham is an Australian entrepreneur whose dog, Rosie, received an experimental vaccine after he used AI tools to help research possible treatments. Her reported improvement brought attention to the case, but specialists say it is difficult to know what caused it because she also received another cancer treatment.
Gamgee aims to offer similar personalised vaccines for dogs and is preparing early clinical trials. The work is part of a broader effort to test whether mRNA-based cancer treatments can be made quickly enough for veterinary care and, eventually, for human medicine.
AI Art Business Companies Culture Health Medicine Technology